BTAIQ IGALMI

Agitation, at-home use · BioXcel · sNDA

Of 100 applications in this same position, about 70 get approved.

Until the FDA deadline40d

Base rate95%

Gap−25pts

PDUFA target date 2026-11-14the FDA may act earlier or later

Summary

We put approval in this review cycle at about 70%, below the ~95% base rate for supplements. The clinical case is reasonable: FDA agreed the content of the submission before filing, and the SERENITY At-Home safety trial met its objective with no drug-related serious adverse events, syncope or falls. Two things weigh heavily against it. First, during the review FDA asked BioXcel to redesign the package's child-resistant feature for home use. As of August the new design had not been submitted, and the company warned this could affect approval by the PDUFA date. Second, BioXcel filed for Chapter 11 on 27 August and is selling the asset to Teva mid-review. An extension is plausible. Confidence is low.

Recorded 2026-10-04 19:58 UTC · v1Proof ↓

Evidence · 6 items

Why 70%, not 95%

Indication

Efficacy supplement to NDA 215390 to allow at-home use without healthcare-provider supervision for acute treatment of agitation associated with bipolar I/II disorder or schizophrenia in adults (SERENITY At-Home)

95% of comparable applications were approved in the past: the opponent every forecast has to beat. Below are the reasons this forecast differs.

▲ supports approval, ▼ counts against it. More squares, more weight.

01▼ AgainstLarge FDA asked mid-review for the child-resistant package to be redesigned for home use, and this was unresolved at last disclosure

The 10-Q filed 2026-08-13 says that during the review FDA requested BioXcel modify the child-resistant feature of IGALMI's primary package for at-home use. The company 'plans to submit' a new design, cannot be sure FDA will accept it in time, and warns this could hurt the chance of approval on the PDUFA date. This was not in the May 10-Q. The current pouch is a tear-open foil pouch. The Teva APA (Aug 27) carves adverse 'human factors study' results on the packaging out of its MAE definition, so that study was apparently still pending. New packaging needs child-resistance and human-factors testing plus stability data, which could bring a major amendment and extension, or a CRL.

Source: BioXcel 10-Q filed 2026-08-13; 10-Q filed 2026-05-15; D. Del. Bankr. Case 26-11360 Doc 13 (Stalking Horse APA, MAE definition); IGALMI label 215390s002
02▼ AgainstMedium The sponsor is in bankruptcy and the asset is being sold during the review

BioXcel filed Chapter 11 on 2026-08-27 after six lender forbearance amendments in July–August. It runs on a DIP budget with minimal staff and was delisted from Nasdaq (trading suspended 2026-09-08). Bid deadline is Oct 9, auction Oct 14, sale hearing Oct 21 and target closing about Oct 26, so ownership of the NDA would likely move to Teva weeks before the action date. That makes it harder to respond quickly to late-cycle requests such as the packaging redesign. Withdrawal (VOID) looks unlikely because the sale price depends on approval.

Source: BioXcel 8-Ks 2026-07-06, 08-03, 08-11, 08-24, 08-25, 08-28, 09-01; bondoro.com case summary
03▲ SupportsSmall The clinical package was agreed with FDA in advance and the safety trial met its objective

Efficacy is already established from the SERENITY I/II pivotal trials behind the approved indication. In August 2025 written pre-sNDA responses, FDA aligned on the clinical, nonclinical and CMC content. SERENITY At-Home (246 randomized, 2,437 treated episodes over 12 weeks, 120 mcg) met its primary safety objective: no discontinuations for tolerability, no drug-related SAEs, no syncope or falls, and no rise in AEs with repeat dosing. Exploratory efficacy favored the drug (mCGI-S p<.05). FDA accepted the filing (PDUFA date set on 2026-04-01).

Source: BioXcel 10-Q filed 2026-08-13; GlobeNewswire 2026-04-01; BioXcel pre-sNDA release 2025-08-18
04▲ SupportsSmall A well-resourced acquirer with a direct incentive to get the supplement approved

Teva's stalking-horse bid pays $57.5M upfront plus $67.5M if the sNDA is approved by 2026-11-21. The milestone falls to $55M (by Feb 28, 2027), $20M (by May 31, 2027) and $5M (by Nov 30, 2027). An unfavorable FDA action does not let Teva terminate. Teva could fund the packaging work after closing. The tiers also show the parties priced in a real chance of delay, which fits a possible 3-month extension.

Source: D. Del. Bankr. Case 26-11360 Doc 13 (motion and Stalking Horse APA section 2.3.2); BioXcel 8-K 2026-08-28
05▼ AgainstSmall This would be the first agitation label without supervision for a drug with hemodynamic warnings

The current label requires administration under healthcare-provider supervision, with vital-sign monitoring, because of hypotension, orthostatic hypotension, bradycardia, QT prolongation and somnolence. Removing supervision may lead FDA to ask for added labeling or risk-management measures. That is more likely to narrow the label than to cause a CRL, given the clean safety data.

Source: IGALMI prescribing information (215390s002, Nov 2025)
06▼ AgainstSmall The sponsor's history of trial-conduct problems

An FDA Form 483 from a December 2022 inspection (disclosed June 2023) and principal-investigator misconduct at a TRANQUILITY II site (a different program) mean BIMO inspections of SERENITY At-Home sites could get extra scrutiny. No problems with SERENITY At-Home have been disclosed.

Source: BioXcel 10-Q filed 2026-08-13 (risk factors); bondoro.com filing alert

What would change this forecast

01
Disclosure that the revised child-resistant package has been submitted and accepted, or that human-factors results are positive (up)
02
A PDUFA extension to about February 2027 for a packaging major amendment: this moves the scoring date, and we would modestly raise approval odds versus a near-term CRL
03
The sale order and closing to Teva, plus any Teva statement on the sNDA timeline
04
News of a CRL, BIMO inspection findings, or a REMS/labeling dispute (down)

Any change is published as a new version; earlier versions stay exactly as they were.

Confidence

Low

Manufacturing and inspection risk

High

The main identified obstacle is CMC/packaging. FDA itself asked for a redesigned child-resistant primary package for home use. As of mid-August the new design had not been submitted, and the human-factors and child-resistance testing results were pending. The film is made by contract manufacturers. The 10-Q also cites scale-up work for the outpatient indication, and the bankrupt sponsor has limited resources to finish this before November 14. We cannot see FDA's specific packaging comments, so the size of this risk is uncertain.

Record · version 1

Written on 2026-10-04, 41 days before the PDUFA target date.

Timeline

Versions

v1 2026-10-04 19:58 UTC 70% Current version JSON ↓.ots ↓ ○ Timestamp submitted, awaiting block confirmation

Fingerprint

SHA-2565d774ce4f79d3e375e897b5976efe0a9b6e5adf7edd81ec707ae51a87e011566

The fingerprint of the v1 file. It is what the timestamp commits to: change one character of the file and the fingerprint no longer matches.

Verify it yourself

Download the JSON file above and the .ots file of the same name into one folder.
Compute the SHA-256 of the file. It should match the fingerprint above.
Verify with OpenTimestamps. Once the timestamp is in a Bitcoin block, ots verify reports the block time if you run a Bitcoin node; without one, drop both files on the verifier at opentimestamps.org, or run ots info to see the block height and look it up in any block explorer. If the block time is before the FDA’s decision, the file cannot have been written afterwards.

pip install opentimestamps-client
shasum -a 256 v1_20261004T195805Z.json
ots verify v1_20261004T195805Z.json.ots
ots info v1_20261004T195805Z.json.ots

Scoring rule

What is scored is the last version recorded at least 2 days before the PDUFA target date; if the FDA decides early, only versions recorded before the day of its decision count. For this forecast the cutoff is 2026-11-12. Its error (also called the Brier score) is the squared distance between the forecast and the outcome, set against the error of quoting the base rate only.